Generic Drugs Market worth USD 675.29 billion by 2030 - Exclusive Report by Precedence Research

The global Generic Drugs Market is projected to reach US$ 675.29 billion by the end of the year 2030, and growing at a CAGR of 5.7% from 2021 to 2030.

 

The latest study collated and published by Precedence Research analyzes the historical and present-day scenario of the global Generic Drugs market in order to accurately gauge its future growth. The study presents detailed information about the important growth factors, restraints, and trends that are creating a landscape for the growth of the global Generic Drugs market so as to identify growth opportunities for market stakeholders. The report also provides insightful information about how the global Generic Drugs market would expand during the forecast period of 2021 to 2030.

Get the Sample Pages of Report@ https://www.precedenceresearch.com/sample/1205

The report offers intricate dynamics about different aspects of the global Generic Drugs market, which aids companies operating in the market in making strategic development decisions. The study also elaborates on significant changes that are highly anticipated to configure growth of the global Generic Drugs market during the forecast period. It also includes a key indicator assessment that highlights growth prospects of the global Generic Drugs market and estimates statistics related to growth of the market in terms of value (US$ Mn) and volume (tons).

This study covers a detailed segmentation of the global Generic Drugs market, along with key information and a competition outlook. The report mentions company profiles of players that are currently dominating the global Generic Drugs market, wherein various developments, expansions, and winning strategies practiced and implemented by leading players have been presented in detail.

Market Segmentation

By Drug Type

• Simple Generics
  • Super Generics

By Brand

• Pure generic drugs

• • Branded generic drugs

By Route of Drug Administration

• Oral
  • Topical
  • Parental
  • Others

By Therapeutic Application

• Central nervous system (CNS)
• Cardiovascular
• Dermatology
• Oncology
• Respiratory
• Others

Key Distribution Channel

• Hospitals Pharmacies
• Retail Pharmacies
• Others

By Geography

• North America
  • • U.S.
    • Canada
• Europe
  • • Germany
    • France
    • United Kingdom
    • Rest of Europe
• Asia Pacific
  • • China
    • Japan
    • India
    • Southeast Asia
    • Rest of Asia Pacific
• Latin America
  • • Brazil
    • Rest of Latin America
• Middle East & Africa (MEA)
• • • GCC
    • North Africa
    • South Africa
    • Rest of Middle East & Africa

Key Players

• Mylan N.V.
• Abbott Laboratories
• ALLERGAN
• Teva Pharmaceutical Industries Ltd.
• Eli Lilly and Company
• STADA Arzneimittel AG
• GlaxoSmithKline Plc.
• Baxter International Inc.
• Pfizer Inc.
• Sandoz International GmbH

Get Customization on this Research Report@ https://www.precedenceresearch.com/customization/1205

Research Methodology

The research methodology adopted by analysts for compiling the global Generic Drugs market report is based on detailed primary as well as secondary research. With the help of in-depth insights of the market-affiliated information that is obtained and legitimated by market-admissible resources, analysts have offered riveting observations and authentic forecasts for the global market.

During the primary research phase, analysts interviewed market stakeholders, investors, brand managers, vice presidents, and sales and marketing managers. Based on data obtained through interviews of genuine resources, analysts have emphasized the changing scenario of the global market.

For secondary research, analysts scrutinized numerous annual report publications, white papers, market association publications, and company websites to obtain the necessary understanding of the global Generic Drugs market.

Table of Content

Chapter 1. Introduction

1.1. Research Objective
1.2. Scope of the Study
1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach
2.2. Data Sources
2.3. Assumptions& Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Generic Drugs Market Variables and Scope

4.1. Introduction
4.2. Market Classification and Scope

Chapter 5. COVID 19 Impact on Generic Drugs Market

5.1. Covid-19: generic drugs Industry Impact
5.2. generic drugs Business Impact Assessment: Covid-19
5.2.1. Services Challenges/Disruption
5.2.2. Market Trends and generic drugs Opportunities in the COVID-19 Landscape for Major Markets
5.3. Strategic Measures against Covid-19
5.3.1. Government Support and Initiative to Combat Covid-19
5.3.2. Proposal for generic drugs Market Players to deal with Covid-19 Pandemic Scenario

Chapter 6. Generic Drugs Market Dynamics Analysis and Trends

6.1. Market Dynamics
6.1.1. Market Drivers
6.1.1.1. The low cost of generics, as an alternative to branded drugs
6.1.1.2. Large number of patent expired branded drugs
6.1.1.3. Initiatives by governments and other regulatory bodies
6.1.2. Market Restraints
6.1.2.1. Stringent governmental regulations and adverse effects associated with drugs
6.1.3. Market Opportunities
6.1.3.1. Use of RPA to ensure regulatory and standards compliance

Chapter 7. Global Generic Drugs Market: Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis
7.1.1.1. generic drugs Market Revenue by Market Players (2017 - 2020)
7.1.1.2. generic drugs Market Revenue Market Share by Market Players (2017 - 2020)
7.1.2. Key Organic/Inorganic Strategies Adopted by Players
7.1.2.1. Product Portfolio Expansion, Geographic Expansion, Product Innovation
7.1.2.2. Merger and Acquisition, Collaboration and Partnerships
7.1.3. Market Players Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of End-users

Chapter 8. Global Generic Drugs Market, By Drug Type

8.1. generic drugs Market, by Drug Type, 2017-2030
8.1.1. Simple Generics
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Super Generics
8.1.2.1. Market Revenue and Forecast (2017-2030)

Chapter 9. Global Generic Drugs Market, By Brand

9.1. generic drugs Market, by Brand, 2017-2030
9.1.1. Pure generic drugs
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Branded generic drugs
9.1.2.1. Market Revenue and Forecast (2017-2030)

Chapter 10. Global Generic Drugs Market, By Route of Drug Administration

10.1. generic drugs Market, by Route of Drug Administration, 2017-2030
10.1.1. Oral
10.1.1.1. Market Revenue and Forecast (2017-2030)
10.1.2. Topical
10.1.2.1. Market Revenue and Forecast (2017-2030)
10.1.3. Parental
10.1.3.1. Market Revenue and Forecast (2017-2030)
10.1.4. Others
10.1.4.1. Market Revenue and Forecast (2017-2030)

Chapter 11. Global Generic Drugs Market, By Therapeutic Application

11.1. generic drugs Market, by Therapeutic Application, 2017-2030
11.1.1. Central nervous system (CNS)
11.1.1.1. Market Revenue and Forecast (2017-2030)
11.1.2. Cardiovascular
11.1.2.1. Market Revenue and Forecast (2017-2030)
11.1.3. Dermatology
11.1.3.1. Market Revenue and Forecast (2017-2030)
11.1.4. Oncology
11.1.4.1. Market Revenue and Forecast (2017-2030)
11.1.5. Respiratory
11.1.5.1. Market Revenue and Forecast (2017-2030)
11.1.6. Others
11.1.6.1. Market Revenue and Forecast (2017-2030)

Chapter 12. Global Generic Drugs Market, By Distribution Channel

12.1. generic drugs Market, by Distribution Channel, 2017-2030
12.1.1. Hospitals Pharmacies
12.1.1.1. Market Revenue and Forecast (2017-2030)
12.1.2. Retail Pharmacies
12.1.2.1. Market Revenue and Forecast (2017-2030)
12.1.3. Others
12.1.3.1. Market Revenue and Forecast (2017-2030)

Chapter 13. Global Generic Drugs Market, Regional Estimates and Trend Forecast

13.1. North America
13.1.1. Market Revenue Forecast by Drug Type(2017-2030)
13.1.2. Market Revenue Forecast by Brand (2017-2030)
13.1.3. Market Revenue Forecast by Route of Drug Administration (2017-2030)
13.1.4. Market Revenue Forecast by Therapeutic Application (2017-2030)
13.1.5. Market Revenue Forecast by Distribution Channel (2017-2030)
13.1.6. U.S
13.1.6.1. Market Revenue Forecast (2017-2030)
13.1.7. Canada
13.1.7.1. Market Revenue Forecast (2017-2030)
13.2. Europe
13.2.1. Market Revenue Forecast by Drug Type (2017-2030)
13.2.2. Market Revenue Forecast by Brand (2017-2030)
13.2.3. Market Revenue Forecast by Route of Drug Administration (2017-2030)
13.2.4. Market Revenue Forecast by Therapeutic Application (2017-2030)
13.2.5. Market Revenue Forecast by Distribution Channel (2017-2030)
13.2.6. UK
13.2.6.1. Market Revenue Forecast (2017-2030)
13.2.7. Germany
13.2.7.1. Market Revenue Forecast (2017-2030)
13.2.8. France
13.2.8.1. Market Revenue Forecast (2017-2030)
13.2.9. Rest of EU
13.2.9.1. Market Revenue Forecast (2017-2030)
13.3. Asia Pacific (APAC)
13.3.1. Market Revenue Forecast by Drug Type (2017-2030)
13.3.2. Market Revenue Forecast by Brand (2017-2030)
13.3.3. Market Revenue Forecast by Route of Drug Administration (2017-2030)
13.3.4. Market Revenue Forecast by Therapeutic Application (2017-2030)
13.3.5. Market Revenue Forecast by Distribution Channel (2017-2030)
13.3.6. China
13.3.6.1. Market Revenue Forecast (2017-2030)
13.3.7. India
13.3.7.1. Market Revenue Forecast (2017-2030)
13.3.8. Japan
13.3.8.1. Market Revenue Forecast (2017-2030)
13.3.9. Rest of APAC
13.3.9.1. Market Revenue Forecast (2017-2030)
13.4. LATAM
13.4.1. Market Revenue Forecast by Drug Type (2017-2030)
13.4.2. Market Revenue Forecast by Brand (2017-2030)
13.4.3. Market Revenue Forecast by Route of Drug Administration (2017-2030)
13.4.4. Market Revenue Forecast by Therapeutic Application (2017-2030)
13.4.5. Market Revenue Forecast by Distribution Channel (2017-2030)
13.4.6. Brazil
13.4.6.1. Market Revenue Forecast (2017-2030)
13.4.7. Rest of LATAM
13.4.7.1. Market Revenue Forecast (2017-2030)
13.5. Middle East and Africa (MEA)
13.5.1. Market Revenue Forecast by Drug Type (2017-2030)
13.5.2. Market Revenue Forecast by Brand (2017-2030)
13.5.3. Market Revenue Forecast by Route of Drug Administration (2017-2030)
13.5.4. Market Revenue Forecast by Therapeutic Application (2017-2030)
13.5.5. Market Revenue Forecast by Distribution Channel (2017-2030)
13.5.6. GCC
13.5.6.1. Market Revenue Forecast (2017-2030)
13.5.7. North Africa
13.5.7.1. Market Revenue Forecast (2017-2030)
13.5.8. South Africa
13.5.8.1. Market Revenue Forecast (2017-2030)
13.5.9. Rest of MEA
13.5.9.1. Market Revenue Forecast (2017-2030)

Chapter 14. Company Profiles

14.1. Abbott Laboratories
14.1.1. Company Overview, Business Information, Regional Presence
14.1.2. Product Portfolio Analysis
14.1.2.1. Product Details, Specification, Application
14.1.3. Revenue, Price, and Gross Margin (2017-2020)
14.1.4. Recent Developments and Strategies
14.2. Teva Pharmaceutical Industries Ltd.
14.2.1. Company Overview, Business Information, Regional Presence
14.2.2. Product Portfolio Analysis
14.2.2.1. Product Details, Specification, Application
14.2.3. Revenue, Price, and Gross Margin (2017-2020)
14.2.4. Recent Developments and Strategies
14.3. ALLERGAN
14.3.1. Company Overview, Business Information, Regional Presence
14.3.2. Product Portfolio Analysis
14.3.2.1. Product Details, Specification, Application
14.3.3. Revenue, Price, and Gross Margin (2017-2020)
14.3.4. Recent Developments and Strategies
14.4. Sandoz International GmbH
14.4.1. Company Overview, Business Information, Regional Presence
14.4.2. Product Portfolio Analysis
14.4.2.1. Product Details, Specification, Application
14.4.3. Revenue, Price, and Gross Margin (2017-2020)
14.4.4. Recent Developments and Strategies
14.5. Mylan N.V.
14.5.1. Company Overview, Business Information, Regional Presence
14.5.2. Product Portfolio Analysis
14.5.2.1. Product Details, Specification, Application
14.5.3. Revenue, Price, and Gross Margin (2017-2020)
14.5.4. Recent Developments and Strategies
14.6. STADA Arzneimittel AG
14.6.1. Company Overview, Business Information, Regional Presence
14.6.2. Product Portfolio Analysis
14.6.2.1. Product Details, Specification, Application
14.6.3. Revenue, Price, and Gross Margin (2017-2020)
14.6.4. Recent Developments and Strategies
14.7. Baxter International Inc.
14.7.1. Company Overview, Business Information, Regional Presence
14.7.2. Product Portfolio Analysis
14.7.2.1. Product Details, Specification, Application
14.7.3. Revenue, Price, and Gross Margin (2017-2020)
14.7.4. Recent Developments and Strategies
14.8. Eli Lilly and Company
14.8.1. Company Overview, Business Information, Regional Presence
14.8.2. Product Portfolio Analysis
14.8.2.1. Product Details, Specification, Application
14.8.3. Revenue, Price, and Gross Margin (2017-2020)
14.8.4. Recent Developments and Strategies
14.9. GlaxoSmithKline Plc.
14.9.1. Company Overview, Business Information, Regional Presence
14.9.2. Product Portfolio Analysis
14.9.2.1. Product Details, Specification, Application
14.9.3. Revenue, Price, and Gross Margin (2017-2020)
14.9.4. Recent Developments and Strategies
14.10. Pfizer Inc.
14.10.1. Company Overview, Business Information, Regional Presence
14.10.2. Product Portfolio Analysis
14.10.2.1. Product Details, Specification, Application
14.10.3. Revenue, Price, and Gross Margin (2017-2020)
14.10.4. Recent Developments and Strategies

Chapter 15. Appendix

15.1. About Us
15.2. Glossary of Terms

Complete Payment Process and Get Full Access of this Research Report@ https://www.precedenceresearch.com/checkout/1205

Contact Us:

Precedence Research

Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada

Call: +1 774 402 6168

Email: sales@precedenceresearch.com

Website: https://www.precedenceresearch.com

Blog: https://precedenceresearchnews.wordpress.com

Follow us on LinkedIn | Twitter | Facebook